About this trial
Cell therapy is an innovative treatment with significant efficacy in hematologic and certain autoimmune diseases. Although it offers potential benefits for autoimmune hemolytic anemia (AIHA), it may result in cognitive and other potential impairments, which can adversely affect patients' cognition and behavior.
Brain function and psychological assessment are essential for the early detection of potential impairments, allowing timely interventions to prevent complications and ensure patient safety. This study aims to comprehensively evaluate the physical and psychological impacts of cell therapy on AIHA patients to develop safer and more effective treatment strategies that enhance their quality of life.
Eligibility criteria
Qualifiers
Diagnosis of AIHA
Subjects will receive cell therapy such as CAR T-cell therapy
Male or female, aged 18-65 years
Willing and able to comply with the requirements for this study and written informed consent
Disqualifiers
History of psychiatric illness
History of severe brain disease
Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study
Trial design
Treatments tested in this trial
- Brain function and psychological assessment
Treatment groups
Sponsors and collaborators
Institute of Hematology & Blood Diseases Hospital, China
Lead sponsor
Tianjin University
Collaborator